Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Neoadjuvant therapy and surgery only (Control) Clear all
Terminated Phase 2 Interventional Results available

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

NCT03259425
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, HF10
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Sep 25, 2026, 9:57 AM EDT
Recruiting Phase 2 Interventional

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

NCT06048484
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat, Etrumadenant, Modified FOLFIRINOX
Radiation · Drug
Lead sponsor
Gulam Manji
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Lake Success, New York • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer

NCT00470184
View directory record Official record
Conditions
Esophageal Cancer
Interventions
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 25, 2026, 9:57 AM EDT
Completed No phase listed Observational

A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients

NCT00407160
View directory record Official record
Conditions
Kidney Diseases
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

NCT07477418
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Active, not recruiting Phase 1 Interventional

Surgical Nivolumab And Ipilimumab For Recurrent GBM

NCT04606316
View directory record Official record
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
Interventions
Nivolumab-Placebo, Nivolumab, Ipilimumab-Placebo, Ipilimumab, Surgery
Drug · Procedure
Lead sponsor
Patrick Wen, MD
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Active, not recruiting Early Phase 1 Interventional

PHL Treatment in Pancreatic Cancer

NCT05365893
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Paricalcitol, Hydroxychloroquine, Losartan, Neoadjuvant therapy and surgery only (Control)
Combination Product · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

NCT03547999
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
mFOLFOX6, MVA-BN-CV301, FPV-CV301, Nivolumab
Drug · Biological
Lead sponsor
Patrick Boland
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 25, 2026, 9:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Paclitaxel, Carboplatin, Bevacizumab, IMNN-001
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

NCT02002182
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
ADXS11-001 (ADXS-HPV)
Biological
Lead sponsor
Andrew Sikora
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 25, 2026, 9:57 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

NCT04373031
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Pembrolizumab, IRX 2
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 25, 2026, 9:57 AM EDT
Not listed Phase 3 Interventional

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

NCT01204801
View directory record Official record
Conditions
Breast Cancer
Interventions
Focused Microwave Thermotherapy, Chemotherapy (control)
Device · Drug
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 25, 2026, 9:57 AM EDT